Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).

Abstract

Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P = .02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.

• Authors: Supriya Perambakam, Hui Xie, Seby Edassery, David J Peace
• Journal: Clinical & developmental immunology (Clin Dev Immunol) Vol. 2010 Pg. 473453 ( 2010) ISSN: 1740-2530 [Electronic] Egypt
• PMID: 21253471 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Cancer Vaccines
• HLA-A2 Antigen
• Hormones
• Peptide Fragments
• Peptides
• prostate-specific antigen (146-154)
• Interferon-gamma
• Prostate-Specific Antigen

Topics

• Aged
• Cancer Vaccines (administration & dosage, adverse effects, immunology)
• HLA-A2 Antigen (metabolism)
• Hormones (immunology)
• Humans
• Hypersensitivity, Delayed (immunology)
• Interferon-gamma (biosynthesis)
• Male
• Middle Aged
• Peptide Fragments (administration & dosage, adverse effects, chemistry, immunology)
• Peptides (administration & dosage, adverse effects, chemistry, immunology)
• Prostate-Specific Antigen (administration & dosage, adverse effects, chemistry, immunology)
• Prostatic Neoplasms (immunology, mortality, therapy)
• Risk Factors
• Vaccination